S100A8 and Sepsis: When released secondarily during a primary acute inflammatory process like sepsis and infection or autoimmune and autoinflammatory reactions, S100A8/A9 amplifies the primary pro-inflammatory response by activating the MyD88-dependent TLR4 signaling pathway (29, 37–42) (Figure 1).